WCN25-4599 ROLE OF METFORMIN IN ADPKD: EXPERIENCE FROM A TERTIARY CARE CENTRE IN EASTERN INDIA
ADPKD, the most common of the inherited renal cystic diseases, accounts for 2.6% cases of CKD in India. Metformin acting via the AMPK pathway has shown to impact cystogenesis and in preclinical animal models retards the progression of ADPKD. Few studies have highlighted the safety profile of Metformin in ADPKD patients but large studies on therapeutic efficacy are lacking. We evaluated the effect of Metformin therapy on the progression of ADPKD by comparing the changes of height adjusted total kidney volume (htTKV) and of estimated glomerular filtration rate (eGFR) in between groups on Metformin and Placebo over a period of 12 months across different Mayo imaging classes
Authors
- Atanu Pal (ORCID: https://orcid.org/0000-0002-2144-6824)
- Dipankar Sircar
- S. SADHUKHAN
- Aniruddha Datta
- Arpita Ray Chaudhury
- Koushik Bhattacharjee (ORCID: https://orcid.org/0000-0002-6000-4113)
- Sanjay Dasgupta
Institutions
- Kolkata Municipal Corporation (IN)
- Institute of Post Graduate Medical Education and Research (IN)
- Medical College and Hospital, Kolkata (IN)
Publication Details
- Journal
- Kidney International Reports
- Published
- 2025-01-27
- DOI
- https://doi.org/10.1016/j.ekir.2024.11.1126
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00